CorMedix Inc (CRMD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
CorMedix Inc stock (CRMD) is currently trading at $6.46. CorMedix Inc PE ratio is 3.06. CorMedix Inc PS ratio (Price-to-Sales) is 1.58. Analyst consensus price target for CRMD is $14.57. WallStSmart rates CRMD as Moderate Buy.
- CRMD PE ratio analysis and historical PE chart
- CRMD PS ratio (Price-to-Sales) history and trend
- CRMD intrinsic value — DCF, Graham Number, EPV models
- CRMD stock price prediction 2025 2026 2027 2028 2029 2030
- CRMD fair value vs current price
- CRMD insider transactions and insider buying
- Is CRMD undervalued or overvalued?
- CorMedix Inc financial analysis — revenue, earnings, cash flow
- CRMD Piotroski F-Score and Altman Z-Score
- CRMD analyst price target and Smart Rating
CorMedix Inc
📊 No data available
Try selecting a different time range
CRMD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · CorMedix Inc (CRMD)
CRMD trades at a significant discount to its Graham intrinsic value of $13.87, offering a 46% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
CorMedix Inc (CRMD) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, price/sales. Concerns around eps growth. Overall metrics suggest strong investment potential with favorable risk/reward.
CorMedix Inc (CRMD) Key Strengths (7)
Every $100 of shareholder equity generates $67 in profit
Keeps $54 of every $100 in revenue after operating costs
Revenue surging 312.10% year-over-year
Keeps $52 of every $100 in revenue as net profit
Paying $1.58 for every $1 of annual revenue
Trading at 1.22x book value, attractively priced
55.15% held by institutions, strong professional interest
Supporting Valuation Data
CorMedix Inc (CRMD) Areas to Watch (2)
Earnings declining -28.30%, profits shrinking
Small-cap company with higher risk but more growth potential
CorMedix Inc (CRMD) Detailed Analysis Report
Overall Assessment
This company scores 70/100 in our Smart Analysis, earning a B- grade. Out of 9 metrics analyzed, 7 register as strengths (avg 9.1/10) while 2 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Revenue Growth. Valuation metrics including Price/Sales (1.58), Price/Book (1.22) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 66.60%, Operating Margin at 53.90%, Profit Margin at 52.30%. Growth metrics are encouraging with Revenue Growth at 312.10%.
The Bear Case
The primary concerns are EPS Growth, Market Cap. Growth concerns include EPS Growth at -28.30%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 66.60% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 312.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and Operating Margin makes a compelling case at current levels. The key risk is EPS Growth, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B- grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CRMD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CRMD's Price-to-Sales ratio of 1.58x trades at a deep discount to its historical average of 1734.83x (0th percentile). The current valuation is 100% below its historical high of 9889.58x set in Dec 2024, and 0% above its historical low of 1.58x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~12.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for CorMedix Inc (CRMD) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
CorMedix Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 312M with 312% growth year-over-year. Profit margins are strong at 52.3%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 312% YoY, reaching 312M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 66.6% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can CorMedix Inc maintain 312%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact CorMedix Inc.
Bottom Line
CorMedix Inc offers an attractive blend of growth (312% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(31 last 3 months)
| Insider | Type | Shares |
|---|---|---|
DILLIONE, JANET Director | Sell | -10,000 |
| Insider | Type | Shares |
|---|---|---|
TODISCO, JOSEPH Director, Chief Executive Officer | Sell | -22,665 |
| Insider | Type | Shares |
|---|---|---|
SECKLER, MICHAEL DAVID Chief Commercial Officer | Buy | +133,156 |
Data sourced from SEC Form 4 filings
Last updated: 1:30:25 PM
About CorMedix Inc(CRMD)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.